Cancer multidrug resistance: a review of recent drug discovery research.

@article{Liscovitch2002CancerMR,
  title={Cancer multidrug resistance: a review of recent drug discovery research.},
  author={Mordechai Liscovitch and Yaakov Lavie},
  journal={IDrugs : the investigational drugs journal},
  year={2002},
  volume={5 4},
  pages={349-55}
}
Conventional cancer chemotherapy is seriously limited by tumor cells exhibiting multidrug resistance (MDR), caused by changes in the level or activity of membrane transporters that mediate energy-dependent drug efflux and of other proteins that affect drug metabolism and/or drug action. Many inhibitors of MDR transporters have been identified and some are undergoing clinical trials, but currently none are in clinical use. Here we briefly review the status of MDR drugs, outline novel approaches… CONTINUE READING
63 Citations
46 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Combination chemotherapy plus PSC 833 followed by interleukin-2 in treating older patients with acute myeloid leukemia

  • National Institutes of Health
  • April 17
  • 2002
Highly Influential
5 Excerpts

Combination chemotherapy with or without PSC 833 in treating patients with relapsed or refractory multiple myeloma

  • National Institutes of Health
  • April 17
  • 2002
Highly Influential
5 Excerpts

Combination chemotherapy with or without PSC 833, peripheral stem cell transplantation, and/or interleukin2 in treating patients with acute myeloid leukemia

  • National Institutes of Health
  • April 17
  • 2002
Highly Influential
5 Excerpts

Intensive compared with nonintensive chemotherapy in treating older patients with acute myeloid leukemia or myelodysplastic syndrome

  • National Institutes of Health
  • April 17
  • 2002
Highly Influential
5 Excerpts

Ontogen appoints Steven S Cowell to Board of Directors

  • Ontogen Corp
  • Press Release
  • 2002
2 Excerpts

P-glycoprotein antagonist, tariquidar, in combination with doxorubicin (adriamycin), vinorelbine (navelbine), or docetaxel to treat children with solid tumors

  • National Institutes of Health
  • April 17
  • 2002
2 Excerpts

Pipeline and products

  • Vertex Pharmaceuticals Inc
  • January 08
  • 2002
2 Excerpts

R101933 combined with chemotherapy in treating patients with metastatic breast cancer that has not responded to previous chemotherapy

  • National Institutes of Health
  • April 17
  • 2002
2 Excerpts

Xenova Group plc preliminary results for the year ended 31 December 2001

  • Xenova Group plc
  • Press Release
  • 2002
2 Excerpts

Similar Papers

Loading similar papers…